This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

tocilizumab (RoActemra®)

Reference No. 1851

Publication date:

Last review date:

Appraisal information

tocilizumab (RoActemra®) 20 mg/ml concentrate for solution for infusion

Company: Roche Products Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: 22/01/2014
AWMSG meeting date: 19/02/2014
Submission Type: Limited Submission
Status: Superseded
Advice No: 0514
Ratification by Welsh Government: 07/05/2014

Current Progress

Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA373) NICE GUIDANCE ISSUED DECEMBER 2015 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Tocilizumab (RoActemra®) is recommended as an option for use within NHS Wales in combination with methotrexate (MTX) for the treatment of juvenile idiopathic polyarthritis (rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. Tocilizumab can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. This recommendation applies only in circumstances where the approved Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
AWMSG Secretariat Appraisal Report (ASAR)
Clinical Expert (CE) Summary